Collegium Pharmaceutical (COLL) Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" COLL shares.
View COLL analyst ratings or view top-rated stocks.

2 Wall Street research analysts have issued 1-year price objectives for Collegium Pharmaceutical's stock. Their COLL share price forecasts range from $35.00 to $36.00. On average, they predict the company's share price to reach $35.50 in the next year. This suggests a possible upside of 58.8% from the stock's current price.
View analysts price targets for COLL or view top-rated stocks among Wall Street analysts.

Collegium Pharmaceutical's stock was trading at $23.20 at the beginning of the year. Since then, COLL stock has decreased by 3.7% and is now trading at $22.35.
View the best growth stocks for 2023 here.

Collegium Pharmaceutical saw a drop in short interest in September. As of September 15th, there was short interest totaling 6,920,000 shares, a drop of 6.5% from the August 31st total of 7,400,000 shares. Based on an average trading volume of 293,000 shares, the days-to-cover ratio is presently 23.6 days. Currently, 20.5% of the shares of the stock are sold short.
View Collegium Pharmaceutical's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our COLL earnings forecast.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) announced its earnings results on Thursday, August, 3rd. The specialty pharmaceutical company reported $1.13 earnings per share for the quarter, beating analysts' consensus estimates of $1.11 by $0.02. The specialty pharmaceutical company had revenue of $135.55 million for the quarter, compared to the consensus estimate of $137.98 million. Collegium Pharmaceutical had a positive trailing twelve-month return on equity of 87.81% and a negative net margin of 2.08%.

ETFs with the largest weight of Collegium Pharmaceutical (NASDAQ:COLL) stock in their portfolio include First Trust Dow Jones Select Microcap Index Fund (FDM), Inspire Fidelis Multi Factor ETF (FDLS), Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG), SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE).

Collegium Pharmaceutical issued an update on its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $565.00 million-$580.00 million, compared to the consensus revenue estimate of $570.46 million.

6 employees have rated Collegium Pharmaceutical Chief Executive Officer Joseph Ciaffoni on Glassdoor.com. Joseph Ciaffoni has an approval rating of 68% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include Galapagos (GLPG), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), Pfizer (PFE), Bausch Health Companies (BHC), Gilead Sciences (GILD) and GW Pharmaceuticals (GWPH).

(COLL) raised $75 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

Shares of COLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of COLL stock can currently be purchased for approximately $22.35.

Collegium Pharmaceutical (NASDAQ:COLL) has a market capitalization of $776.22 million and generates $463.93 million in revenue each year. The specialty pharmaceutical company earns $-25,000,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis.

The company employs 207 workers across the globe.

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The official website for the company is www.collegiumpharma.com. The specialty pharmaceutical company can be reached via phone at (781) 713-3699 or via email at info@collegiumpharma.com.